X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA PANACEA BIOTECH PLETHICO PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x -1.1 84.6 - View Chart
P/BV x 0.0 1.9 0.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
PANACEA BIOTECH
Mar-14
PLETHICO PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs395149 265.6%   
Low Rs3182 38.0%   
Sales per share (Unadj.) Rs604.484.1 718.3%  
Earnings per share (Unadj.) Rs32.5-18.3 -177.4%  
Cash flow per share (Unadj.) Rs51.3-6.7 -766.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.683.7 565.7%  
Shares outstanding (eoy) m34.0861.25 55.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.4 25.7%   
Avg P/E ratio x6.6-6.3 -104.0%  
P/CF ratio (eoy) x4.2-17.2 -24.1%  
Price / Book Value ratio x0.51.4 32.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2627,074 102.7%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m1,5961,449 110.1%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m20,5985,154 399.7%  
Other income Rs m386100 387.1%   
Total revenues Rs m20,9845,254 399.4%   
Gross profit Rs m2,818-766 -367.7%  
Depreciation Rs m642711 90.3%   
Interest Rs m1,5931,503 106.0%   
Profit before tax Rs m969-2,881 -33.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m-13817 -823.7%   
Profit after tax Rs m1,107-1,121 -98.7%  
Gross profit margin %13.7-14.9 -92.0%  
Effective tax rate %-14.3-0.6 2,449.8%   
Net profit margin %5.4-21.8 -24.7%  
BALANCE SHEET DATA
Current assets Rs m18,8773,810 495.4%   
Current liabilities Rs m11,8968,365 142.2%   
Net working cap to sales %33.9-88.4 -38.3%  
Current ratio x1.60.5 348.4%  
Inventory Days Days36156 23.1%  
Debtors Days Days19867 294.2%  
Net fixed assets Rs m9,86114,480 68.1%   
Share capital Rs m34161 555.8%   
"Free" reserves Rs m12,331903 1,365.4%   
Net worth Rs m16,1395,127 314.8%   
Long term debt Rs m4,7065,832 80.7%   
Total assets Rs m33,14619,433 170.6%  
Interest coverage x1.6-0.9 -175.4%   
Debt to equity ratio x0.31.1 25.6%  
Sales to assets ratio x0.60.3 234.3%   
Return on assets %8.12.0 414.7%  
Return on equity %6.9-21.9 -31.4%  
Return on capital %12.33.6 338.0%  
Exports to sales %21.424.5 87.2%   
Imports to sales %15.210.2 149.5%   
Exports (fob) Rs m4,4021,264 348.3%   
Imports (cif) Rs m3,136525 597.6%   
Fx inflow Rs m4,4021,539 286.0%   
Fx outflow Rs m3,184942 338.0%   
Net fx Rs m1,219597 204.0%   
CASH FLOW
From Operations Rs m2,437599 406.8%  
From Investments Rs m-6,265-438 1,430.6%  
From Financial Activity Rs m2,490-303 -822.9%  
Net Cashflow Rs m-1,337-141 946.3%  

Share Holding

Indian Promoters % 82.7 74.5 111.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 0.6 716.7%  
FIIs % 5.5 1.3 423.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 23.6 31.8%  
Shareholders   10,665 10,259 104.0%  
Pledged promoter(s) holding % 85.7 35.1 244.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS